Literature DB >> 13404465

Some important aspects of yaws eradication.

C J HACKETT, T GUTHE.   

Abstract

The purposes of a yaws mass campaign are to eradicate yaws and to improve the environmental sanitation and standard of living of the people so that its re-introduction will be impossible. In a mass treatment campaign the importance of latent cases and contacts in maintaining the disease must be taken into account. The treatment of this group of the population, in addition to all active cases, hastens the success of the campaign.Resurveys at regular intervals must be carried out until the prevalence of active yaws is low and there are adequate facilities to continue the consolidation phase of the campaign. All the population should be seen at each survey. Serological screening is used to guide public health activities.All campaigns and post-campaign activities should be planned and budgeted for before the activities start. Campaigns should expand as compact areas and should be co-ordinated with similar campaigns in adjacent countries. Adequate supervision of field staff, the intelligent co-operation of the people and their leaders and continuous project evaluation are essential for the eradication of yaws.

Entities:  

Keywords:  YAWS/prevention and control

Mesh:

Year:  1956        PMID: 13404465      PMCID: PMC2538179     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  5 in total

1.  Experience with yaws control in Indonesia; preliminary results with a simplified approach.

Authors:  M SOETOPO; R WASITO
Journal:  Bull World Health Organ       Date:  1953       Impact factor: 9.408

2.  Yaws control; an opportunity for promoting rural health-services.

Authors:  J L TROUPIN; F W REYNOLDS; T GUTHE
Journal:  Bull World Health Organ       Date:  1953       Impact factor: 9.408

3.  Extent and nature of the yaws problem in Africa.

Authors:  C J HACKETT
Journal:  Bull World Health Organ       Date:  1953       Impact factor: 9.408

4.  A yaws campaign in Sierra Leone.

Authors:  R D HARDING
Journal:  Trans R Soc Trop Med Hyg       Date:  1949-01       Impact factor: 2.184

5.  Serological study of yaws in Java.

Authors:  H Y LI; R SOEBEKTI
Journal:  Bull World Health Organ       Date:  1955       Impact factor: 9.408

  5 in total
  25 in total

1.  Treatment of early venereal syphilis with antibiotics.

Authors:  R R WILLCOX
Journal:  Br J Vener Dis       Date:  1962-09

2.  Equipment and technique of intramuscular injection in mass treatment campaigns against the treponematoses.

Authors:  C J HACKETT; C W GOCKEL
Journal:  Bull World Health Organ       Date:  1958       Impact factor: 9.408

3.  Evolutionary cycle of the treponematoses.

Authors:  R R WILLCOX
Journal:  Br J Vener Dis       Date:  1960-06

4.  Some epidemiological aspects of yaws eradication.

Authors:  C J HACKETT
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

5.  Attenuated yaws in Surinam.

Authors:  P L Niemel; E A Brunings; H E Menke
Journal:  Br J Vener Dis       Date:  1979-04

6.  Methods for the surveillance of endemic treponematoses and sero-immunological investigations of "disappearing" disease.

Authors:  T Guthe; J Ridet; F Vorst; J D'Costa; B Grab
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

7.  The rise and fall of the treponematoses. II. Endemic treponematoses of childhood.

Authors:  T Guthe; O Idsoe
Journal:  Br J Vener Dis       Date:  1968-03

8.  Selective mass treatment in a venereal disease control program.

Authors:  H W Jaffe; D T Rice; R Voigt; J Fowler; R K St John
Journal:  Am J Public Health       Date:  1979-11       Impact factor: 9.308

9.  Endemic treponematoses in the Sudan. A report on a survey.

Authors:  E I GRIN
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

10.  ON THE ORIGIN OF THE HUMAN TREPONEMATOSES (PINTA, YAWS, ENDEMIC SYPHILIS AND VENEREAL SYPHILIS).

Authors:  C J HACKETT
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.